(Hypertension. 2000;36:303.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
From the Division of Clinical Sciences (NGH) (A.G.P.), Northern General Hospital, Herries Road, Sheffield, UK; and Department of Medicine (R.W., J.F.), Units of Rheumatology and CMM and of Cardiovascular Medicine (C.L., U. de F.), Karolinska Hospital, and Department of Medicine (R.K.), Department of Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.
Correspondence to Graham Pockley, PhD, Division of Clinical Sciences (NGH), Clinical Sciences Centre, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK. E-mail g.pockley{at}sheffield.ac.uk or to Johan Frostegård, MD, Department of Medicine, Unit of Rheumatology and CMM, Karolinska Hospital, 17176 Stockholm, Sweden.
| Abstract |
|---|
|
|
|---|
Key Words: heat shock proteins hypertension, borderline atherosclerosis human
| Introduction |
|---|
|
|
|---|
Although heat shock proteins are typically regarded as being intracellular, they can be expressed on the surface of mononuclear cells8 9 and stressed aortic endothelial cells.10 They can also be released from cultured rat glial and human islet cells,11 12 and Hsp60 and Hsp70 have been identified in the serum of healthy individuals.13 14 Given the potential involvement of heat shock proteins in the pathogenesis of vascular disease and the association between hypertension and atherosclerosis,15 we determined the levels of circulating Hsp60; Hsp70; and antihuman Hsp60, antihuman Hsp70, and antimycobacterial 65-kDa protein antibodies in normotensive (NT) and BHT subjects. We make the novel observation that circulating levels of Hsp60 are increased in BHT subjects.
| Methods |
|---|
|
|
|---|
80 mm Hg on both occasions. BP
measurements were made by the same nurse. The study was approved by the local ethics committee of the Karolinska Hospital and was conducted in accordance with the Helsinki Declaration. All subjects gave informed consent.
Study Program
All subjects were investigated according to the same
schedule.7 BHT patients and their NT counterparts were
assessed simultaneously whenever possible or no more than 4
weeks apart. Blood samples were taken after the participant rested for
15 minutes in the supine position between 8:00 AM and 9:30
AM after a fast of 8 to 12 hours.
Analysis of Total Serum Immunoglobulin Levels
Serum IgG, IgM, and IgA levels were determined with
immunoturbidometry (Hitachi 911 analyzer) with anti-IgG,
anti-IgM, and anti-IgA reagents and calibrators (DAKO).
Serum Hsp60 and Hsp70 levels
Serum Hsp60 and Hsp70 levels were determined with
immunoassay.13 14 Briefly, 96-well microtitre plates (Nunc
Immunoplate Maxisorp; Life Technologies) were coated through overnight
incubation at 4°C with murine monoclonal antibodies to human Hsp60
(clone LK.1.) or Hsp70 (clone C92F3A-5; StressGen) in carbonate buffer,
pH 9.5 (2 µg/mL). Plates were washed with PBS containing 1% vol/vol
Tween 20 (PBS/T) and blocked by incubation with 1% wt/vol bovine serum
albumin in PBS/T.
Serum samples were added, and bound heat shock protein was detected by the addition of rabbit polyclonal anti-Hsp60 or anti-Hsp70 antibody (1:1000; SPA-804 and SPA-812; StressGen). Bound polyclonal antibody was detected with alkaline phosphatase-conjugated murine monoclonal antibody to rabbit immunoglobulins (Sigma Chemical Co), followed by p-nitrophenyl phosphate substrate (Sigma Chemical Co). The resultant absorbance was measured at 405 nm with a Titertek Multiscan MCC/340 plate reader. Standard dose-response curves were generated in parallel with recombinant human Hsp60 (0 to 2500 ng/mL) or Hsp70 (0 to 20 000 ng/mL; StressGen), and the concentrations of Hsp60 and Hsp70 were determined by reference to these standard curves with ASSAYZAP data analysis software (BIOSOFT). The interassay variability of the Hsp60 and Hsp70 immunoassays was <10%.13 14
Serum AntiHeat Shock Protein Antibody Levels
Heat shock protein antibody levels were also determined as
described previously.13 14 17 Microtiter plates were
coated with recombinant human Hsp60 (StressGen), recombinant human
Hsp70 (StressGen), or recombinant Mycobacterium
bovis Hsp65 (100 µL, 2 µg/mL). M. bovis Hsp65
was provided by the UNDP/World Bank/WHO Special Program for Research
and Training in Tropical Diseases (Braunschweig, Germany).
Plates were washed, and nonspecific binding sites were blocked. Serum samples (typically 1:100 in PBS/T) were added, and bound antibodies were detected with alkaline phosphatase conjugated polyclonal goat anti-human IgA/G/M (Sigma Chemical Co) followed by p-nitrophenyl phosphate substrate substrate. Antibody concentrations were determined by comparison with a standard curve that was generated with samples of predetermined high levels that had been assigned a concentration of 1000 arbitrary units/mL (AU/mL).
Plasma Lipoprotein and Insulin Levels
Serum VLDL-, LDL-, and HDL-cholesterol and
triglyceride levels were determined as described
previously.7 The major plasma lipoprotein fractions were
determined with preparative ultracentrifugation and
lipid analyses of the lipoprotein fractions.18
Venous blood samples were also taken for the determination of blood
glucose (Kodak Ectachem) and plasma insulin (radioimmunoassay; Kabi
Pharmacia) levels.
Carotid Ultrasonography
The right and left carotid arteries were examined with a duplex
scanner (Acuson 128XP/5) with a 7.0-MHz linear-array transducer.
Subjects were investigated in the supine position with the head turned
slightly away from the sonographer. The intima-media (I/M) thickness
was determined as described previously.15 Plaque was
defined as localized I/M thickening, with a thickness of >1 mm
and a 100% increase in thickness compared with normal, adjacent wall
segments; it was scored as being present or absent.7
The common, internal, and external carotid arteries on both sides were
screened.
Statistical Methods
Variables were tested for skewness and groups with skewed
variables were compared by the nonparametric
Mann-Whitney U test. The Students t test was
used for the comparison of normally distributed data. Categorical
variables were compared by the
2 test. The
Spearman rank correlation was used to assess interrelationships among
heat shock proteins, heat shock protein antibodies,
metabolic variables, and BP levels. Nonnormally
distributed variables were logarithmically transformed. Data are
presented as mean±SEM for normally distributed data and as
median and first and third quartile (Q25 and
Q75) values for nonnormally distributed data. The
level of statistical significance was set at a value of
P<0.05.
| Results |
|---|
|
|
|---|
|
BHT men had a significantly altered metabolic profile with fasting hyperinsulinemia and dyslipoproteinemia (Table 1), as has been reported previously.19 In the BHT group, 26% of the subjects had detectable carotid plaques on 1 or both sides, whereas the incidence in the NT group was 16% (19 versus 10 subjects, NS).
Heat Shock Protein and Heat Shock Protein Antibody Levels
Hsp60 levels were markedly higher in the BHT group
(P=0.001), whereas there was no significant difference in
Hsp70 levels (Table 2). Hsp60 was
present in all of the patients with BHT (100%) and 73 of the 75
control subjects (97%). Circulating Hsp70 was detectable in 36 of the
65 individuals with BHT (55%) and 37 of the 75 control subjects
(49%).
|
Antihuman Hsp60, antihuman Hsp70, and antimycobacterial Hsp65 antibodies were detected in all of the BHT samples analyzed. Anti-Hsp60 antibodies were detected in all 75 of the control samples, but there were 10 individuals who were negative for antimycobacterial Hsp65 antibodies and 2 individuals who were negative for anti-Hsp70 antibodies. The antimycobacterial Hsp65 antibody levels were significantly higher in the BHT group (P<0.001; Table 2), which confirms previous findings in the same patient group.7 In contrast to anti-Hsp65 antibody levels, antihuman Hsp60 antibodies were significantly lower in the BHT group, although the differences were quantitatively small (P<0.03; Table 2). Anti-Hsp70 antibody levels in the BHT group were not different than those in NT subjects (Table 2).
Relationships Among Hsp, Anti-Hsp Antibodies, I/M Thickness, BP
Levels, and Metabolic Variables
There were significant associations between Hsp60 and DBP
(r=0.34, P<0.0001) and 24-hour systolic
BP (SBP; r=0.179, P=0.037) in the complete study
group. There also was a trend toward an association between Hsp60 and
SBP and 24-hour DBP, but this was not of statistical significance.
Furthermore, anti-Hsp65 antibody levels were associated with DBP
(r=0.187, P=0.028) but not with SBP
(r=0.146, P=0.087) or 24-hour DBP
(r=0.159, P=0.07). There was no relationship
between Hsp70 and anti-Hsp70 antibody levels with BP.
Given that DBP in subjects >60 years old plateaus and that there is an increasing relevance of SBP in subjects in that age group, data were also analyzed according to SBP of >140 mm Hg (n=39) or <140 mm Hg (n=106). The pattern was comparable to that observed when DBP was used. There was a trend for Hsp60 (P=0.072) and anti-Hsp65 (P=0.098) levels to be higher and anti-Hsp60 levels to be lower (P=0.023). Hsp70 and anti-Hsp70 levels did not differ significantly between patients and control subjects.
There was no significant association between heat shock proteins or heat shock protein antibody levels and BP parameters when the BHT and NT groups were analyzed separately.
I/M thickness was associated with Hsp60 levels in the entire group (I/M sin r=0.236, P=0.009; I/M dex r=0.255, P=0.004). This association was present in the BHT group alone (I/M sin r=0.236, P=0.009; I/M dex r=0.255, P=0.004) but not in the NT group. Hsp60 levels were higher in those individuals with carotid atherosclerosis than in those without (n=29; 4354±1885 versus 1885±702 ng/mL, mean±SEM), although this difference was not of statistical significance. However, there was a trend toward Hsp60 levels and atherosclerosis being associated in the BHT group (P=0.06).
Serum Hsp60 levels were associated with VLDL (P=0.017) and triglyceride (P=0.05) levels, but there was no association between Hsp70 or anti-heat shock protein antibody with blood lipids or metabolic factors, nor was there a significant associations between LDL and any of the heat shock proteinrelated parameters. There was no correlation between smoking status and any of the heat shock protein parameters measured (data not shown).
There was no difference in immunoglobulin levels between the BHT group and controls (IgG 9.71±1.9 versus 9.76±2.3 mg/mL, IgM 2.25±0.8 versus 2.1±0.9 mg/mL, respectively), thus excluding the possibility that differences in antibody levels simply reflected altered total antibody levels.
| Discussion |
|---|
|
|
|---|
The evidence for a heat shock proteinmediated component to
atherosclerosis has arisen from a number of studies.
The intensity of heat shock protein expression positively correlates
with the severity of atherosclerosis, there is a
localized enrichment of
/
T cells in the lesion,20
and immunization with recombinant mycobacterial Hsp65 can induce
atherosclerotic lesions in normocholesterolemic
rabbits.21 Elevated levels of circulating antibody to the
mycobacterial 65-kDa heat shock protein have been reported in carotid
atherosclerosis5 and coronary
heart disease.6 The in vivo
physiological significance of heat shock protein
antibodies in the pathogenesis of vascular disease has yet to be
clearly established. However, they have been shown to mediate
endothelial cell cytotoxicity,22 and the
observation that anti-Hsp65/60 antibodies in individuals with
atherosclerosis recognize 3 distinct, conserved
sequences may implicate them in the initiation of
atherosclerosis via an autoimmune type of
mechanism.23
BHT is a condition that exhibits only minor cardiovascular changes, and the presence of circulating Hsp60 and antimycobacterial Hsp65 antibodies may reflect early vascular events. Raised BP has direct effects on the vasculature,24 25 and vessels subjected to greater mechanical and shear stress express heat shock proteins and are more prone to the development of atherosclerosis.20 22 25 26 In addition, Hsp70 mRNA levels are enhanced in hypertensive animals,27 28 and there is a greater accumulation of heat stressinduced Hsp70 mRNA in peripheral blood lymphocytes from hypertensive humans compared with that in NT control subjects.29 Although these findings demonstrate a stress response to hypertension, a definitive causative link between heat shock protein expression/release and the development of vascular disease has yet to be established.
It may be that the heat shock protein expression in the vasculature serves to protect against the effects of physiological and pathological insults such as mechanical stress, shear stress, hypercholesterolemia, free radicals, cytokines, and infections.30 The proposition has been that heat shock protein release is part of a response to protect neighboring cells,11 and this is supported by the observation that Hsp70 enhances the survival of stressed cultured arterial smooth muscle cells.31 32 However, it is possible that heat shock proteins potentiate later stages of atherogenesis by inducing heat shock protein antibodies,5 6 22 by the recruitment of heat shock proteinspecific inflammatory lymphocyte populations,20 or by their expression on the endothelial cell surface.10
The putative involvement of heat shock proteins in the establishment
and progression of the atherosclerotic lesion is undoubtedly complex.
Heat shock protein expression may be secondary to the inflammatory
process, in that the expression of cytokines by both the
vascular endothelium and infiltrating leukocyte
populations drives the expression or release of heat shock proteins
from the vessel wall. Human atherosclerotic plaques express a spectrum
of inflammatory cytokines, including interferon-
,
interleukin-1
and -1ß, and tumor necrosis
factor-
,33 34 all of which have been shown to increase
heat shock protein expression in a range of cell
types.35 36 37 38 39 Alternatively, the localized expression of
heat shock proteins may promote the production of
cytokines, the enhanced expression of adhesion molecules, and
the establishment and propagation of the inflammatory response. A
number of studies lend support to this proposition. Bacterial and
mycobacterial heat shock proteins induce proinflammatory
cytokine expression,40 41 42 and bacterial heat
shock proteins (DNAk and GroEL) induce intercellular adhesion
molecule-1 and vascular cell adhesion molecule-1 expression on human
vascular endothelial cells.40 Chlamydial
and human Hsp60 activate human vascular
endothelial cells to express E-selectin, intercellular
adhesion molecule-1, and vascular cell adhesion molecule-1 and
activate vascular endothelial cells, smooth
muscle cells, and macrophages to secrete
interleukin-6.43 Heat shock proteins may also be expressed
by lipid-laden "foam" cells in the atherosclerotic plaque, in that
in vitro exposure to oxidized LDL induces Hsp60 expression by monocytic
cell lines39 and Hsp70 expression by human
endothelial cells.44
This is the first report of increased circulating heat shock protein levels in BHT. Their nature and origin in normal and diseased states have yet to be identified, as have the mechanisms that underlie their release and the influence that released proteins exert on physiological processes. The relationship between circulating heat shock proteins and antiheat shock protein antibodies is undoubtedly complex, and additional studies with an aim of characterizing the circulating protein, defining its relationship with serum antibody, and elucidating its physiological importance are clearly warranted.
Acknowledgments
This work was supported by the Swedish Medical Research Council,
the Swedish Heart Lung Foundation, the King Gustav V 80th Birthday
Fund, the Swedish Society of Medicine, and The Swedish Rheumatism
Association. This study also received financial support from Vasogen
Inc (Mississauga, Canada) and the UNDP/World Bank/WHO Special Program
for Research and Training in Tropical Diseases (TDR). We are grateful
to Joey Shepherd for performing the heat shock protein immunoassays and
to Ulla Hellmark for the blood pressure measurements. We are also
grateful to Anders Hamsten for help with lipoprotein fractionation,
Saud Efendic for help with insulin analysis, and Birger
Andersson for help with analysis of total antibody levels.
Received October 21, 1999; first decision December 10, 1999; accepted February 17, 2000.
| References |
|---|
|
|
|---|
ß
or 
receptor in human atherosclerotic lesions. Am J
Path. 1993;142:19271937.[Abstract]
This article has been cited by other articles:
![]() |
X. Zhang, M.-A. He, L. Cheng, L. Zhou, H. Zeng, J. Wang, F. Wang, Y. Chen, F. B. Hu, and T. Wu Joint Effects of Antibody to Heat Shock Protein 60, Hypertension, and Diabetes on Risk of Coronary Heart Disease in Chinese Clin. Chem., June 1, 2008; 54(6): 1046 - 1052. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gupta and A. A. Knowlton HSP60 trafficking in adult cardiac myocytes: role of the exosomal pathway Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3052 - H3056. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Shamaei-Tousi, J. P. Halcox, and B. Henderson Stressing the obvious? Cell stress and cell stress proteins in cardiovascular disease Cardiovasc Res, April 1, 2007; 74(1): 19 - 28. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Steptoe, A. Shamaei-Tousi, A. Gylfe, L. Bailey, S. Bergstrom, A. R. Coates, and B. Henderson Protective Effect of Human Heat Shock Protein 60 Suggested by Its Association with Decreased Seropositivity to Pathogens Clin. Vaccine Immunol., February 1, 2007; 14(2): 204 - 207. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Wick The Heat Is on: Heat-Shock Proteins and Atherosclerosis Circulation, August 29, 2006; 114(9): 870 - 872. [Full Text] [PDF] |
||||
![]() |
A. Shamaei-Tousi, J. W. Stephens, R. Bin, J. A. Cooper, A. Steptoe, A. R.M. Coates, B. Henderson, and S. E. Humphries Association between plasma levels of heat shock protein 60 and cardiovascular disease in patients with diabetes mellitus Eur. Heart J., July 1, 2006; 27(13): 1565 - 1570. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Romics Jr, G. Szabo, J. C. Coffey, J. H. Wang, and H. P. Redmond The Emerging Role of Toll-Like Receptor Pathways in Surgical Diseases Arch Surg, June 1, 2006; 141(6): 595 - 601. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-i. Yokota, S. Minota, and N. Fujii Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors Int. Immunol., April 1, 2006; 18(4): 573 - 580. [Abstract] [Full Text] [PDF] |
||||
![]() |
S G Baidya and Q-T Zeng Helper T cells and atherosclerosis: the cytokine web Postgrad. Med. J., December 1, 2005; 81(962): 746 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Xiao, K. Mandal, G. Schett, M. Mayr, G. Wick, F. Oberhollenzer, J. Willeit, S. Kiechl, and Q. Xu Association of Serum-Soluble Heat Shock Protein 60 With Carotid Atherosclerosis: Clinical Significance Determined in a Follow-Up Study Stroke, December 1, 2005; 36(12): 2571 - 2576. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P.J. Halcox, J. Deanfield, A. Shamaei-Tousi, B. Henderson, A. Steptoe, A. R.M. Coates, A. Singhal, and A. Lucas Circulating Human Heat Shock Protein 60 in the Blood of Healthy Teenagers: A Novel Determinant of Endothelial Dysfunction and Early Vascular Injury? Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): e141 - e142. [Full Text] [PDF] |
||||
![]() |
A G Pockley and J Frostegard Heat shock proteins in cardiovascular disease and the prognostic value of heat shock protein related measurements Heart, September 1, 2005; 91(9): 1124 - 1126. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Bausero, R. Gastpar, G. Multhoff, and A. Asea Alternative Mechanism by which IFN-{gamma} Enhances Tumor Recognition: Active Release of Heat Shock Protein 72 J. Immunol., September 1, 2005; 175(5): 2900 - 2912. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Frostegard Atherosclerosis in Patients With Autoimmune Disorders Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1776 - 1785. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Foteinos, A. R. Afzal, K. Mandal, M. Jahangiri, and Q. Xu Anti-Heat Shock Protein 60 Autoantibodies Induce Atherosclerosis in Apolipoprotein E-Deficient Mice via Endothelial Damage Circulation, August 23, 2005; 112(8): 1206 - 1213. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Hagg, M. E. Johansson, J. Gronros, A. S. Naylor, I. H. Jonsdottir, G. Bergstrom, P.-A. Svensson, and L.-m. Gan Gene expression profile and aortic vessel distensibility in voluntarily exercised spontaneously hypertensive rats: potential role of heat shock proteins Physiol Genomics, August 11, 2005; 22(3): 319 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Habich, K. Kempe, R. van der Zee, R. Rumenapf, H. Akiyama, H. Kolb, and V. Burkart Heat Shock Protein 60: Specific Binding of Lipopolysaccharide J. Immunol., February 1, 2005; 174(3): 1298 - 1305. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Martin-Ventura, M. C. Duran, L. M. Blanco-Colio, O. Meilhac, A. Leclercq, J.-B. Michel, O. N. Jensen, S. Hernandez-Merida, J. Tunon, F. Vivanco, et al. Identification by a Differential Proteomic Approach of Heat Shock Protein 27 as a Potential Marker of Atherosclerosis Circulation, October 12, 2004; 110(15): 2216 - 2219. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-F. Tsan and B. Gao Cytokine function of heat shock proteins Am J Physiol Cell Physiol, April 1, 2004; 286(4): C739 - C744. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Buhlin, A. Gustafsson, A.G. Pockley, J. Frostegard, and B. Klinge Risk factors for cardiovascular disease in patients with periodontitis Eur. Heart J., December 1, 2003; 24(23): 2099 - 2107. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Pockley, A. Georgiades, T. Thulin, U. de Faire, and J. Frostegard Serum Heat Shock Protein 70 Levels Predict the Development of Atherosclerosis in Subjects With Established Hypertension Hypertension, September 1, 2003; 42(3): 235 - 238. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Gao and M.-F. Tsan Recombinant Human Heat Shock Protein 60 Does Not Induce the Release of Tumor Necrosis Factor {alpha} from Murine Macrophages J. Biol. Chem., June 13, 2003; 278(25): 22523 - 22529. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhu, A. A. Quyyumi, H. Wu, G. Csako, D. Rott, A. Zalles-Ganley, J. Ogunmakinwa, J. Halcox, and S. E. Epstein Increased Serum Levels of Heat Shock Protein 70 Are Associated With Low Risk of Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., June 1, 2003; 23(6): 1055 - 1059. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Xu Role of Heat Shock Proteins in Atherosclerosis Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1547 - 1559. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Pockley Heat Shock Proteins, Inflammation, and Cardiovascular Disease Circulation, February 26, 2002; 105(8): 1012 - 1017. [Full Text] |